

***Ehrlichia canis* Genes and Vaccines**

FIELD OF THE INVENTION

The invention pertains to the field of veterinary pathogens. More particularly, the present invention pertains to the sequence of specific genes of the bacterial canine pathogen *Ehrlichia canis* and the application of this technology to the development of a vaccine.

BACKGROUND OF THE INVENTION

The present invention relates to the sequence of genes from the *E. canis* bacterium, and the development of a vaccine against this organism.

Ehrlichia canis (*E. canis*) is a small gram-negative, obligately intracytoplasmic rickettsia. This bacteria is the agent which causes canine monocytic ehrlichiosis (CME), a tick-borne disease which predominantly affects dogs. The most common carrier of *E. canis* is the brown dog tick *Rhipicephalus sanguineus*. The disease was described originally in Algeria in 1935. It was subsequently recognized in the United States in 1962, but is now known throughout much of the world. Canine monocytic ehrlichiosis caused much concern during the Vietnam War, when 160 military dogs died from the *E. canis* infection. There is no vaccination currently available against *E. canis*. It is a life threatening disease that continues to be an important health concern for veterinarians and pet owners alike.

Canine monocytic ehrlichiosis is an infectious blood disease. A reduction in cellular blood elements is the primary characteristic of the disease. *E. canis* lives and reproduces in the white blood cells (leukocytes). It eventually affects the entire lymphatic system, and devastates multiple organs. By targeting the white blood cells, these cells die off rapidly. These dead blood cells migrate primarily to the spleen, which enlarges as a

result. The bone marrow recognizes the loss of the white blood cells and works to form new, healthy cells. It sends out the cells prematurely, and these immature cells do not work properly. Often, these immature cells mimic those in leukemic patients, so the disease is misdiagnosed as leukemia. Canine monocytic ehrlichiosis may also predispose dogs to various cancers.

There are three stages of canine monocytic ehrlichiosis. The first, acute stage mimics a mild viral infection. During the acute stage, most, if not all, of the damage is reversible and the animal is likely to recover. This is the stage where treatment is the most effective, stressing the need for early detection. Without treatment, however, the animal will progress into a subclinical (second) stage and/or to the chronic (final) stage. When the animal has reached the chronic stage, the bacterial organism has settled within the bone marrow. Many dogs in this stage suffer massive internal hemorrhage, or develop lethal complications such as sudden stroke, heart attack, renal failure, splenic rupture or liver failure.

E. canis can be cultured *in vitro* in a mammalian-derived cell line (DH82). Continued maintenance of these cells is difficult because the cell culture must be supplemented with primary monocytes (white blood cells found in bone marrow) every two weeks. The cultures are very slow growing, and the culture media is expensive.

Data concerning the genes in the *E. canis* genome has concentrated primarily on the 16S rRNA gene. Previous work has sequenced this gene, which is a ubiquitous component of the members of the ehrlichia family, as well as the majority of organisms worldwide. The high sequence homology between this gene throughout the living world and its poor immunogenicity makes it an unsuitable candidate for vaccine development. It is necessary to find other genes within this genome if hope for a vaccine against this deadly disease can ever be realized.

Sequencing of the 16S rRNA gene indicates that *E. canis* is closely related (98.2% homology) to *E. chaffeensis*, the novel etiologic agent of human ehrlichiosis. Western blots of *E. canis* are similar when probed with antisera to *E. canis*, *E. chaffeensis*, and *E. ewingi* (another cause of human ehrlichiosis) indicating a close antigenic relationship between these three species (Chen *et al.*, 1994).

The indirect fluorescent antibody test (IFA) has been developed for detecting canine monocytic ehrlichiosis. IFA detects the presence of antibodies against the invading organism in a dog's blood. Unfortunately, this test is not always accurate. Sometimes, dogs will test negative in the acute phase because their immune system is delayed in forming antibodies. Another false negative may occur if there is a low titer in the chronic stage. An additional drawback of this test is the cross-reactivity found. The anti *E. canis* polyclonal antibody positively reacts with *E. chaffeensis*, undermining the specificity of the test. An alternative test, the Giesma smear, has been used to locate the actual organism in a dog's blood. Unfortunately, despite appropriate staining techniques and intensive film examination, the organisms frequently can not be located. The fallibility of these tests makes it essential to provide better diagnostic tools for this disease.

Due to difficulties in the detection of a tick bite, early diagnosis of infection, the suppression of host defenses and the nature of persistent infection of the disease, an effective vaccine against *E. canis* is urgently needed for dogs.

SUMMARY OF THE INVENTION

This invention discloses novel sequence data for *E. canis* genes. Specifically, a clone has been identified and sequenced. Four proteins termed ProA, ProB, *mmpA* (for morula membrane protein, which is an ORF), and a cytochrome oxidase homolog, have been identified within this clone. In addition, a partial gene encoding a lipoprotein signal peptidase homolog has been discovered.

An embodiment of this invention includes the creation of a vaccine with this sequence and protein information. The proteins disclosed in this invention are extremely antigenic. Therefore, they have the potential to be extremely useful as a vaccine. The types of vaccine made available by this novel technology include a DNA vaccine, a recombinant vaccine, and a T cell epitope vaccine.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 shows the three clones identified in the library screen.

DESCRIPTION OF THE PREFERRED EMBODIMENT

E. canis causes a devastating canine disease. Currently, there is no vaccine available to prevent this disease. This invention provides the tools necessary to develop such a vaccine. More specifically, four genes have been identified from a genomic fragment of *E. canis*, named ProA, ProB, *mmpA*, and a cytochrome oxidase homolog. In addition, a partial gene coding for a lipoprotein signal peptidase homolog has been found. Any of these proteins can be utilized in an embodiment of this invention to develop a vaccine.

Screening an *E. canis* library

To identify genes in the *E. canis* genome, a genomic DNA expression library was constructed. An *E. canis* strain isolated from dogs with canine ehrlichiosis was grown in the dog cell line DH82 by a technique being known in the art, and incorporated by reference (Dawson *et al.*, 1991; Rikihisa, 1992). The cells were harvested and the chromosomal DNA extracted as described by a technique known in the art (Chang *et al.*, 1987; Chang *et al.*, 1989a; Chang *et al.*, 1989b; Chang *et al.*, 1993a; Chang *et al.*, 1993b). To construct the library, 200 µg of DNA was partially digested with *Sau3A*. DNA fragments from 3 to 8 kb were isolated and ligated to a plasmid, pHG165 (Stewart *et al.*, 1986). The plasmids were transformed into *E. coli* TB1 (Chang *et al.*, 1987).

The library was screened with polyclonal antibodies against *E. canis*. Polyclonal antibodies were generated from dogs that had been bitten by a tick harboring *E. canis*. The polyclonal antibodies were preabsorbed with the lysate of an *E. coli* host strain. The library was plated on petri plates at a density of 1,000 colony forming units. Colonies were transferred to nitrocellulose and each filter was probed with 1 ml of the preabsorbed polyclonal antibodies. Positive colonies were identified with a second antibody consisting of an alkaline phosphatase-conjugated goat anti-rabbit IgG (Kirkegaard and Perry

Laboratories, Gaithersburg, MD), followed by color development with a substrate solution containing nitroblue tetrazolium (NBT) and 5-bromo-4-chloro-3-indolyl phosphate (BCIP). Positive clones were rescreened three times.

Three clones were isolated from this screening procedure, pCH2, 4, and 5 (Figure 1). Within these three positive clones, an overlapping reading frame was found that codes for mmpA. The longest genomic fragment (pCH4) encodes four complete genes and one partial gene. It completely encodes the proteins ProA, ProB, *mmpA*, and a cytochrome oxidase homolog, as well as containing the partial sequence of a lipoprotein signal peptidase homolog. ProA and ProB are located on a single operon. Restriction endonuclease digestion mapping and DNA sequencing were done by techniques known in the art, and incorporated by reference (Chang *et al.*, 1987; Chang *et al.*, 1989a; Chang *et al.*, 1989b; Chang *et al.*, 1993a; Chang *et al.*, 1993b). Briefly, the DNA sequence was determined by automated DNA sequencing on the ABI PRISM Model 377 DNA system. The complete nucleotide sequences were determined on both strands by primer walking. The thermal cycling of the sequencing reactions utilized the Taq DyeDeoxy™ Terminator Cycle sequencing kit. Databases were searched for homologous proteins through the use of the BLAST network service of the National Center for Biotechnology Information (NCBI) (Althchul *et al.*, 1990; Gish *et al.*, 1993).

Sequence Information

The *E. canis* genes were sequenced. The cloned fragment contains 5,299 nucleotides, and codes for four proteins. There is also one partial gene at the carboxy terminus. SEQ. ID. NO. 1 is the entire nucleotide sequence. SEQ. ID. NO. 2 and 3 are the translation of nucleotides 12 through 533 from SEQ. ID. NO. 1 and code for a cytochrome oxidase homolog, which was deemed *ec3* and encodes a product of 174 amino acids. Cytochrome oxidase is important in virulence, and therefore is a strong candidate for use in a vaccine. SEQ. ID. NO. 4 and 5 are the translation of nucleotides 939 through 2,252 from SEQ. ID. NO. 1 and code for ProA. ProA begins 402 nucleotides downstream from the end of *ec3* and encodes a product of 438 amino acids. The ProA protein shares extensive characteristics with the putrilysin family, which is a subset of metallopeptidases. The highest homology is seen in the N-terminal portion, which includes conserved

putative metal binding sequence, His-X-X-Glu-His as well as conserved Glu for catalysis. ProA was also shown to share 27% of its characteristics over 284 amino acids with MPP- β (mitochondrial processing peptidase) in *Solanum tuberosum* (Genbank accession number X80237) and 27% of its characteristics over 222 amino acids with *E. Coli* pitrilysin (Genbank accession number M17095). Many bacterial zinc proteases are also found to share homology with ProA protein, such as PqqF in *M.extorquens* AM1 where 36% of 376 amino acids are shared (Genbank accession number L43135), Y4wA in *Rhizobium* sp. where 34% of 416 amino acids are shared (Genbank accession number AE000103), 27% of 419 amino acids of the putative gene product PA0372 in *Pseudomonas aeruginosa* (Genbank accession number AE004475), and 26% of 389 amino acids of the putative gene product of HP1012 in *Helicobacter pylori*, strain 26695 are shared (Genbank accession number AE000609). SEQ. ID. NO. 6 and 7 are the translation of nucleotides 2,258 through 3,610 from SEQ. ID. NO. 1 and code for ProB. ProB begins 6 nucleotides after the end of *proA* and encodes a protein of 451 amino acids long. Through Blast analysis it was shown that ProB does not contain the conserved Zinc-binding domain. ProB was shown to share homology with both subunits of the MPP subfamily and some bacterial putative zinc proteases such as PqqF, Y4wA, and the gene products of PA0372. ProB also shared homology with bacterial proteases that do not contain Zinc-ligand motif, but show similarities with the pitrilysin family, such as PqqG, Y4wB, gene product of PA0371, and the gene product of HP0657 in *M. extorquens* AM1, *Rhizobium* sp., *P. aeruginosa*, and *H. pylori* 26695. Preliminary evidence indicates that ProA and ProB are proteases. SEQ. ID. NO. 8 and 9 are the translation of nucleotides 4,132 through 4,794 from SEQ. ID. NO. 1 and code for ORF, designated mmpA. The polypeptide that is generated consists of 221 amino acids and does not have a significant identity to any proteins found in existing databases. SEQ. ID. NO. 10 and 11 are the translation of the complementary sequence of nucleotides 4,883 through 5,299 from SEQ. ID. NO. 1 and code for the partial sequence of a lipoprotein signal peptidase homolog. Lipoprotein signal peptidases are membrane proteins, and by nature may be less desirable for vaccine development. However, this protein is still worth pursuing in the creation of a vaccine.

Structure and Expression of ProA, ProB, mmpA, cytochrome oxidase and the lipoprotein signal

Structurally, MmpA is extremely hydrophobic with five transmembrane segments and three potential antigenic determinants, which are protein kinase C phosphorylation sites located in position 7 (Ser), 37 (Ser), and 213(Ser) and one possible casein kinase II phosphorylation site in position 177 (Thr), where the above determinants were characterized by PROSITE and the PCgene programs. MmpA was localized primarily in the morula membrane. Since MmpA contains three potential phosphorylation sites, this indicates the possibility of a similar communication system as seen by phosphorylation of one of the chlamydial inclusion membrane proteins, *IncA*. *E. canis* grown in vitro (DH82 cells) expressed MmpA, furthermore, sera obtained from dogs that were naturally infected and experimentally infected with *E. canis* recognized MmpA, which confirms that in vivo and in vitro expression of MmpA as well as the antigenicity of MmpA. The above two results indicate that MmpA is capable of stimulating an immune response, which is necessary for a vaccine to be effective. However, *E. canis* is an intracellular organism, cell mediated immunity is more important in protecting the dog against this type of infection than humoral immunity and it may be possible to direct these antigens toward a predominant Th1 response using an appropriate adjuvant. The mmpA gene was found in *E. canis* and *E. chaffeensis* but was not present in the HGE agent. However, the MmpA protein was not expressed by *E. chaffeensis* on a western blot. *E. canis* with MmpA caused cells to lyse, indicating the presence of MmpA protein, where *E. chaffeensis* with MmpA did not lyse. This result lends to the conclusion that the MmpA protein may be useful for serodiagnosis in differentiating *E. canis* and *E. chaffeensis*. Furthermore, MmpA, ProA, and ProB proteins can be used as antigens in ELISA or Western blot analysis to perform a diagnosis of an *E. canis* infection in animals.

Structurally, ProA and ProB are very similar except for the fact that ProA contains a catalytic zinc-binding motif and ProB does not contain any catalytic residues. ProA and ProB were localized to the soluble cytoplasmic and periplasmic protein portion, where a tiny amount of ProA was detectable in the inner membrane fraction of the bacterial fractions that were collected to do subcellular fractionation to determine a subcellular location. *E. canis* and *E. chaffeensis* infected DH82 cells both lysed that contained anti-

rProA antibodies, showing that both *E. canis* and *E. chaffeensis* express ProA in culture. Furthermore, both naturally and experimentally infected dogs with *E. canis* infected DH82 cells recognize rProA and rProB leading to the conclusion that ProA and ProB are expressed in vivo and in vitro. However, ProB was not detectable in a western blot using anti-rProB antibodies with *E. chaffeensis*. *E. canis* did detect anti-rProB antibodies. This result shows that ProB may serve as a tool for serological differentiation of *E. canis* and *E. chaffeensis*. Antisera from naturally and experimentally infected dogs with *E. canis* contained antibodies recognizing rProA and rProB. Serum from an uninfected dog did not recognize either of the two proteins. Immunofluorescence staining of *E. canis* in DH82 cells with rabbit anti-rProA and anti-rProB sera was performed, both ProB and ProA antiserum strongly label the intracellular ehrlichial organisms, showing that ProA and ProB can serve as target antigens and that anti-rProA and anti-rProB sera can be used for indirect immunofluorescent assays (IFA) diagnosis. Recombinant ProB can be used as an antigen in ELISA or Western blot analysis to perform a diagnosis of an *E. canis* infection in animals.

Overexpression of ProA, ProB, ORF, cytochrome oxidase and the lipoprotein signal peptidase homolog

The *E. canis* antigens are overexpressed in a T7 promoter plasmid. The pRSET vector allows high level expression in *E. coli* in the presence of T7 RNA polymerase, which has a strong affinity for the T7 promoter. After subcloning the antigen genes into the pRSET vector, the subclones are transformed into an F' *E. coli* JM109 strain. For maximum protein expression, the transformants are cultured to O.D. 600=0.3, exposed to IPTG (1 mM) for one hour and then transfected with M13/T7 bacteriophages at a multiplicity of infection (MOI) of 5-10 plaque forming units (pfu) per cell. Time course studies indicate that maximum induction is reached two hours after induction.

The pellet is harvested by centrifugation and the cells are resuspended in 6M Guanidinium (pH 7.8). Cells are ruptured by French press and the total lysate is spun at 6000 rpm to separate cell debris by a technique known in the art, and hereby incorporated by reference (Chang *et al.*, 1993c). Immobilized metal ion affinity chromatography

(IMAC) is used to purify each of the proteins under denaturing conditions as described by the manufacturer (Invitrogen, San Diego, CA). The protein samples are separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and visualized after staining with coomassie blue.

Diagnosis Techniques: KELA ELISA, Western Blotting (Immunoblots), and PCR

The recombinant ProA, ProB, and MmpA proteins are useful diagnostic agents. One diagnostic technique where the ProA, ProB, and MmpA proteins are used is kinetic enzyme linked immunosorbent assay (KELA ELISA), as described by a technique known in the art (Appel *et al.*, 1993; Chang *et al.*, 1995). KELA measures the levels of serum antibodies to *E. canis* that is present. In this diagnostic technique, diluted serum (1:100 dilution) is added to duplicate wells in microtiter plates that contain antigens of MmpA, ProA, and ProB. The antigens are prepared by French-pressing them. The bound antibodies are then detected by using second antibodies of a goat anti-canine antibody of heavy and light chain specificity conjugated to horseradish peroxidase (HRP). Color development is seen and measured using the chromogen tetramethylbenzidine with H_2O_2 as a substrate, which is measured kinetically and expressed as the slope of the reaction rate between the enzyme and substrate solution. Each unit of slope is designated as a KELA unit. The cutoff point between positive and negative samples is then confirmed by Western blotting against French-pressed *E. canis*.

The procedure for Western blot analysis, as described by a technique known in the art (Appel *et al.*, 1993; Chang *et al.*, 1995), is performed. Recombinant ProA, ProB, and MmpA are used as antigens and are subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Western blot analysis is performed in a miniblotted. Test sera from experimental animals are used as a first antibody, followed by goat anti-dog IgG conjugated to HRP as a second antibody. Bands are developed by using substrates, such as 24 μ g of 4-chloro-1-naphthol in 8 ml of methyl alcohol, 40 ml of Tris-buffer solution, and 24 μ l of 30% H_2O_2 .

Another diagnostic technique recombinant ProA, ProB, and MmpA proteins can be used for is PCR diagnosis. The DNA from biopsy samples of skin or from post mortem tissues or blood are extracted as described by a technique known in the art (Chang *et al.*,

1998a; Chang *et al.*, 1998b). To prevent contamination of the mixtures and samples, DNA extraction, amplification, and detection of PCR products are all performed in different rooms. Amplification of *E. canis* MmpA, ProA, or ProB-specific target sequences is carried out in a 50- μ l reaction mixture. As a positive control, *E. canis* genomic DNA is used. As a negative control distilled water is used. The reaction mixture is then put through 40 cycles of amplification using an automated DNA thermal cycler. Each cycle involves heating the reaction mixture to 94°C for 1 minute, to cause the DNA to denature; cooling of the reaction mixture to 69°C for 1 minute, to allow the primers to anneal; and then heating the reaction mixture to 72°C for 2 minutes, to allow primer extension to occur. Gel electrophoresis on a 1.5% agarose gel is done in order to get visualization of the PCR amplification products.

Vaccine Development

Prior to the present invention, no vaccine against *E. canis* had been developed. *E. canis* is endemic in dogs and closely related canidae in many parts of the world. Dogs in North America are also increasingly at risk and the application of the present invention can potentially save the lives of thousands of dogs each year. An *E. canis* vaccine that can elicit cell-mediated immunity against this tick-borne disease of dogs is desperately needed.

DNA Vaccine

A DNA vaccine is constructed by subcloning the gene of interest into a eukaryotic plasmid vector. Candidate vectors include, but are not limited to, pcDNA3, pCI, VR1012, and VR1020. This construct is used as a vaccine.

Each of the newly identified genes, ProA, ProB, mmpA, the cytochrome oxidase homolog, or the partial lipoprotein signal peptidase homolog can be used to create a DNA vaccine (reviewed in Robinson, 1997). In addition, any immunologically active portion of these proteins is a potential candidate for the vaccine. A plasmid containing one of these genes in an expression vector is constructed. The gene must be inserted in the correct orientation in order for the genes to be expressed under the control of eukaryotic promoters. Possible promoters include, but are not limited to, the cytomegalovirus (CMV)

immediate early promoter, the human tissue plasminogen activator (t-PA) gene (characterized in Degen *et al.*, 1986), and the promoter/enhancer region of the human elongation factor alpha (EF-1 α) (characterized in Uetsuki *et al.*, 1989). Orientation is identified by restriction endonuclease digestion and DNA sequencing.

Expression of these gene products is confirmed by indirect immunofluorescent staining of transiently transfected COS cells, CHO cells, or other suitable cells. The same plasmid without these genes is used as a control. Plasmid DNA is transformed into *Escherichia coli* DH5 α . DNA is purified by cesium chloride gradients and the concentration is determined by a standard protocol being known in the art, and incorporated by reference (Nyika *et al.*, 1998).

Once the DNA is purified, the vector containing the insert DNA can be suspended in phosphate buffer saline solution and directly injected into dogs. Inoculation can be done via the muscle with a needle or intravenously. Alternatively, a gene gun can be used to transport DNA-coated gold beads into cells by a technique known in the art, and hereby incorporated by reference (Fynan *et al.*, 1993). The rationale behind this type of vaccine is that the inoculated host expresses the plasmid DNA in its cells, and produces a protein that raises an immune response. Each of the newly identified genes can be used to create a vaccine by this technique.

CpG molecules can be used as an adjuvant in the vaccine. This technique is known in the art, and is hereby incorporated by reference (Klinman *et al.*, 1997). Adjuvants are materials that help antigens or increase the immune response to an antigen. The motifs consist of an unmethylated CpG dinucleotide flanked by two 5' purines and two 3' pyrimidines. Oligonucleotides containing CpG motifs have been shown to activate the immune system, thereby boosting an antigen-specific immune response. This effect can be utilized in this invention by mixing the CpG oligonucleotides with the DNA vaccine, or physically linking the CpG motifs to the plasmid DNA.

Immunofluorescence staining of *E. canis* in DH82 cells with rabbit anti-rProA and anti-rProB sera was performed, both ProB and ProA antiserum strongly label the intracellular ehrlichial organisms, showing that ProA and ProB can serve as target antigens

and that anti-rProA and anti-rProB sera can be used for indirect immunofluorescent assays (IFA) diagnosis, making the DNA vaccine a viable option to combat this disease.

Recombinant Vaccine

In order to develop a recombinant vaccine, each of the genes is individually subcloned into overexpression vectors, and then purified for vaccine development. ProA, ProB, mmpA, the cytochrome oxidase homolog, or the partial lipoprotein signal peptidase homolog is expressed in a plasmid with a strong promoter such as the tac, T5, or T7 promoter. Alternatively, immunologically active fragments of these proteins are used in the development of a vaccine. Each of these genes is subcloned into a plasmid and transformed into an *E. coli* strain as described above.

The recombinant protein is overexpressed using a vector with a strong promoter. Vectors for use in this technique include pREST (Invitrogen Inc., CA), pKK233-3 (Pharmacia, CA), and the pET system (Promega, WI), although any vector with a strong promoter can be used. After overexpression, the proteins are purified and mixed with adjuvant. Potential adjuvants include, but are not limited to, aluminum hydroxide, QuilA, or Montamide. The purified protein is used as immunogen to vaccinate dogs by a technique being known in the art, and incorporated by reference (Chang *et al.*, 1993c; Chang *et al.*, 1995). Briefly, the individual protein is expressed and purified from *E. coli*. Then, the dogs are injected intramuscularly or subcutaneously with the purified recombinant vaccine and adjuvant. This injection elicits an immune response.

T Cell Epitope Vaccine

Direct cell cytotoxicity mediated by CD8⁺ T lymphocytes (CTL) is the major mechanism of defense against intracellular pathogens. These effector lymphocytes eliminate infected cells by recognizing short peptides associated with MHC class I molecules on the cell surface. Exogenous antigens enter the endosomal pathway and are presented to CD4⁺ T cells in association with class II molecules whereas endogenously synthesized antigens are presented to CD8⁺ T cells in association with MHC class I molecules. *E. canis* is an intracellular pathogen that resides in monocytes and macrophages. The present invention develops novel ways of generating an *E. canis*-

specific CTL response that would eliminate the organism from monocytes or macrophages of infected animals.

A strategy for increasing the protective response of a protein vaccine is to immunize with selective epitopes of the protein. The rationale behind this is that an epitope vaccine contains the most relevant immunogenic peptide components without the irrelevant portions. Therefore, a search is performed for the most highly antigenic portions of the newly identified proteins.

To identify T-cell epitopes from the newly discovered proteins, an initial electronic search for homologous sequences to known T-cell epitopes is performed. In addition, extensive T-cell epitope mapping is carried out. Each of the proteins, ProA, ProB, mmpA, the cytochrome oxidase homolog, and the partial lipoprotein signal peptidase homolog, is tested for immunogenic peptide fragments. Mapping of T cell epitopes by a technique known in the art is hereby incorporated by reference (Launois *et al.*, 1994; Lee and Horwitz, 1999). Briefly, short, overlapping peptide sequences (9-20 amino acids) are synthesized over the entire length of the protein in question. These short peptide fragments are tested using healthy dogs, which have been immunized with the protein of interest. Peripheral blood mononuclear cells from the dogs are tested for T cell stimulatory and IFN- γ inducing properties. Those fragments which elicit the strongest response are the best candidates for a T-cell epitope vaccine.

Once fragments are identified which will make the best epitopes, a recombinant adenylate cyclase of *Bordetella bronchiseptica* is constructed carrying an *E. canis* CD8⁺ T cell epitope. The adenylate cyclase toxin (CyaA) of *Bordetella bronchiseptica* causes disease in dogs and elicits an immune response. In addition, CyaA is well suited for intracytoplasmic targeting. Its catalytic domain (AC), corresponding to the N-terminal 400 amino acid residues of the 1,706-residue-long protein, can be delivered to many eukaryotic cells, including cells of the immune system. Also, toxin internalization is independent of receptor-mediated endocytosis, suggesting that the catalytic domain can be delivered directly to the cytosol of target cells through the cytoplasmic membrane. The *Pseudomonas aeruginosa* exotoxin A (PE) is another toxin which could be used in this

procedure to deliver peptides or proteins into cells, by a technique known in the art, and hereby incorporated by reference (Donnelly *et al.*, 1993).

Foreign peptides (16 residues) have been inserted into various sites of the AC domain of CyaA without altering its stability or catalytic and calmodulin-binding properties. Thus, protein engineering allows the design and delivery of antigens that specifically stimulate CTLs. The induction of specific CD8⁺ T cells can play an important role in canine ehrlichiosis control due to the intracellular persistence of *E. canis* in monocytes.

The adenylate cyclase (AC) toxin (*cya*) gene of *B. bronchiseptica* has been cloned. A synthetic double-stranded oligonucleotide encoding a 9 to 20 amino acid class I T cell epitope of either ProA, ProB, mmpA, the cytochrome oxidase homolog, or the partial lipoprotein signal peptidase homolog, is designed according to *B. bronchiseptica* codon usage. The complementary oligonucleotides are inserted in the hypervariable region of the cloned AC-coding sequence of the *cya*. This technique is known in the art in other systems, and is incorporated by reference (Sebo *et al.*, 1995; Guermonprez *et al.*, 1999).

Recombinant plasmids carrying the chimeric *cya* gene are sequenced to determine the copy number and orientation of the inserted epitope. A plasmid with a complete copy of the insert that specifies the T-cell epitope (CD8⁺) in the correct orientation is chosen from the sequenced plasmids. The ability of the new chimeric protein to enter eukaryotic cells is necessary to ensure intracellular targeting of the epitopes (Fayolle *et al.*, 1996).

A vaccine can be created in one of two ways. Recombinant chimeric protein can be purified and used to inoculate dogs. Alternatively, an attenuated *B. bronchiseptica* strain that carries a T-cell epitope or *E. canis* gene by in-frame insertion into adenylate cyclase is created by allelic-exchange. Allelic-exchange is a technique known in the art, and is hereby incorporated by reference (Cotter and Miller, 1994).

Finally, protection against *E. canis* infection in dogs vaccinated with the adenylate cyclase- ProA, ProB, mmpA, cytochrome oxidase homolog, or lipoprotein signal peptidase homolog chimeric protein is determined. Wild type and recombinant ACs and CyAs are diluted to working concentrations in PBS and the chimeric protein is injected

into dogs either intramuscularly or subcutaneously. Alternatively, the T-cell epitope is inserted into the adenylate cyclase gene of an attenuated *B. bronchiseptica* strain in frame, and the dogs are given the live bacteria.

Recombinant antigens are promising candidates for human and animal vaccination against various pathogens. However, a serious drawback is the poor immunogenicity of recombinant antigens as compared to native antigens. A major challenge in the development of a new recombinant vaccine is, therefore, to have a new adjuvant system that increases the immunogenicity of antigens. Cytokines are powerful immunoregulatory molecules. Cytokines which could be used as adjuvants in this invention include, but are not limited to, IL-12 (interleukin-12), GM-CSF (granulocyte-macrophage colony stimulating factor), IL-1 β (interleukin-1 β) and γ -IFN (gamma interferon).

These cytokines can have negative side effects including pyrogenic and/or proinflammatory symptoms in the vaccinated host. Therefore, to avoid the side effects of a whole cytokine protein, an alternate approach is to use synthetic peptide fragments with the desired immunostimulatory properties. The nonapeptide sequence VQGEESNDK of IL-1 β protein is endowed with powerful immuno-enhancing properties, and is discussed here to illustrate the use of a cytokine to increase immunogenicity.

This nonapeptide is inserted into the ProA, ProB, mmpA, the cytochrome oxidase homolog, or the partial lipoprotein signal peptidase homolog protein and its immunogenicity is compared to that of the native protein. Reportedly, the insertion of this sequence into a poorly immunogenic recombinant antigen increases the chance of a strong protective immune response after vaccination. This peptide could enhance the *in vivo* immune response against both T-dependent and T-independent antigens. The canine IL-1 β sequence may mimic many immunomodulatory activities of the entire molecule of IL-1 β while apparently lacking many of its undesirable proinflammatory properties. This strategy is employed to increase the immunogenicity of ProA, ProB, mmpA, cytochrome oxidase, the partial lipoprotein signal peptidase homolog and other *E. canis* antigens.

Plasmid pYFC199 is derived from a pBR322 plasmid by the insertion of a fragment that includes the ProA, ProB, mmpA, the cytochrome oxidase homolog, or the partial lipoprotein signal peptidase protein from *E. canis*. This plasmid contains a unique

HindIII site where in-frame insertions encoding exogenous sequences can be inserted. Two complementary oligonucleotides, SEQ. ID. NO. 12 and SEQ. ID. NO. 13, that encode the canine IL-1 β 163-171 peptide are annealed, cut with *HindIII*, and inserted into the pYFC199 *HindIII* site. The recombinant plasmid carrying the chimeric IL-1 β gene is sequenced to determine the orientation of the inserted epitope.

The efficacy of the recombinant proteins as vaccines is tested in dogs. The purified protein is injected intraperitoneally into dogs. Specific pathogen free (SPF) dogs are divided into five groups: one group is given recombinant adenylate cyclase of *Bordetella bronchiseptica* carrying *E. canis* CD8⁺ T cell epitopes derived from ProA, ProB, mmpA, cytochrome oxidase homolog, or the partial lipoprotein signal peptidase homolog, one group is given recombinant adenylate cyclase of *Bordetella bronchiseptica* as a control, one group is given the ProA, ProB, mmpA, cytochrome oxidase homolog, or the partial lipoprotein signal peptidase homolog protein plus a canine IL-1 β 163-171 insert, one group is given a T cell epitope derived from ProA, ProB, mmpA, cytochrome oxidase homolog, or the partial lipoprotein signal peptidase homolog alone, and the last group is given PBS as a negative control.

All animals are vaccinated (30-40 μ g each) two times. The dogs are challenged ten days after the last vaccination with 10⁷ *E. canis*. At day five postchallenge, approximately 1 ml blood from each dog is collected in an EDTA tube. Whether the vaccinated groups eliminate the organisms as compared to that of the control group is tested by culture and PCR. Two primers derived from the genes cloned can be used to amplify the gene product from the tissues or blood samples from these dogs. The internal primer can also be designed for use as an oligonucleotide probe to hybridize the PCR gene product.

This invention provides a badly needed vaccine against the *E. canis* bacterium. The vaccine can be used to protect dogs throughout the world from canine monocytic ehrlichiosis.

Accordingly, it is to be understood that the embodiments of the invention herein described are merely illustrative of the application of the principles of the invention. Reference herein to details of the illustrated embodiments are not intended to limit the

scope of the claims, which themselves recite those features regarded as essential to the invention.

10004494.40001

SEQUENCE LISTING

<110> Cornell Research Foundation
Chang, Yung-Fu

<120> Ehrlichia canis Genes for Vaccine Development

<130> CRF 2322 CIP

<160> 18

<170> PatentIn version 3.1

<210> 1

<211> 5299

<212> DNA

<213> Ehrlichia canis

<220>

<221> gene

<222> (1)..(5299)

<223>

<400> 1

```

gatcaaataa aatgaaacca agaataagaa acactattta tggattaata gcaataatac      60
tatctatgat atgttttagtg tacgcttctg taccactata tagtatattt tgtaaagtaa      120
caggttatgg aggtacagta agaacaagta atatatcaaa ttctaaaata ggtaacacta      180
ttattaaagt cagatttaat gcagatatac acaacaact gccatggaaa ttctatccag      240
aagtatctca tgtatttgta aaaccaggag aacaaaaatt gattttctac cgcgcagaaa      300
atctacttga tgaggacact tcaggaatgg ctgtatataa tgttacacca cataaagtag      360
gaaaatatatt taataaggta gcttggtttt gtttcaccaa acaaacatta taccctcatc      420
aaaaaactat aatgccagta tcatttttta tagatccagc catagaaaca gatcctgaaa      480
ctgctgacgt aaaactcatc actctttcat atgtattctt taagtacaaa gaataaactt      540
catataccgt acattataaa ctgattaataa aaaataacta ttaatataga gcaaaaataat      600
ttatctattc aacagattct tttcaattag agagtattca aaaacactac aactactgct      660
tgcaactttc tatcactgat atataaaagt gaaataaatt taaaaaactt tagttttaat      720
agaagaatth tattaaaagc tttgaatcaa atttaattac tgatataaaa atactattaa      780

```

acattaacaa	tgcttaatta	aagtattatt	atttacctta	atttcataac	ctttattaac	840
aatttcataa	taaaaatact	ttactcttat	ttttttatca	cttgatatta	ttaaataatc	900
atataaactc	ccaaataaac	tattgcaagg	ttatggtaat	gatgaaattt	tttacttggt	960
ttttcatagt	tttcttaaca	atagccaatc	atgctttatc	ctttaacatt	aaagttacac	1020
atgaaaaatt	agataatgga	atggaagtat	acgtgattcc	aatcatcgc	gcaccagcag	1080
tcatgcacat	ggtattatac	aaagtcggtg	gaactgatga	tccagtagga	tactctggat	1140
tagcacattt	ttttgaacac	ttaatgttta	gtggaacaga	aaaatttcct	aatctcatca	1200
gcacacttag	taatataggc	ggaaatttca	atgcaagcac	atctcaattt	tgtactatat	1260
actacgaatt	aataccaaaa	caatatttat	ctcttgcaat	ggatattgaa	tcagacagaa	1320
tgcagaattt	taaggttacc	gacaaagcat	taataagaga	acaaaaggta	gtcttagaag	1380
aaagaaaaat	gagagttgaa	agccaagcaa	aaaacatact	agaagaagaa	atggaaaatg	1440
cattttatta	caatggatat	ggcagaccag	tagtaggatg	ggaacatgaa	attagcaact	1500
acaacaaaga	agttgctgaa	gcctttcata	agctacatta	tagtcctaata	aatgctatat	1560
taattgtaac	tggagatgca	gatccacaag	aagtaatcac	acttgcaaaa	caatactatg	1620
ggaaaatacc	atctaataat	aagaaacctt	caagtcaagt	tagggtagaa	ccaccgcata	1680
aaacaaatat	gactttaaca	ttaaagaca	gttcagtaga	aatcccagaa	ctgtttttaa	1740
tgtatcaaat	accaaattgt	attaccaata	aaaactacat	acttaacatg	atgttagcag	1800
aaatactcgg	tagtggtaaa	ttcagcctgc	tttacaatga	tttggttaatt	aacaatccaa	1860
tagttacatc	gataaaaaaca	gattataaatt	acttaactga	cagcgataat	tacctttcca	1920
ttgaagctat	acctaaaaaac	gggatctcta	cagaagctgt	agaacaagaa	attcataaat	1980
gtataaataa	ttattttagaa	aatggaattt	cagcagaata	tttagaaagt	gcaaagtata	2040
aagtaaaagc	acatttaact	tatgcatttg	acggactaac	tttcatatca	tattttttatg	2100
gcatgcatct	aatactagga	gtaccgctat	cagaaatcag	taatatttac	gataccatag	2160
acaaagtaag	tatccaagat	gttaactccg	ctatggaaaa	tatctttcaa	aacaatataa	2220
gattaaccgg	gcattttatta	cctaattggag	aatagttatg	agaaacatat	tgtgttacac	2280
attaatatgg	attttctttt	cattcaatac	atatgcaaat	gatctcaata	ttaacataaa	2340
agaagctaca	actaaaaata	aaatacacta	tctatatgtt	gaacatcata	acctaccaac	2400
aatttcctta	aaatttgcat	tcaagaaagc	aggatacgct	tatgatgcct	ttgataagca	2460
aggacttgca	tactttacat	caaaaatatt	aaacgaagga	tcaaaaaaca	actatgctct	2520

cagttttgca	caacaattag	aaggcaaagg	tatagactta	aaatttgata	tagacctaga	2580
caatttttat	atatcattaa	aaaccttatc	agaaaacttt	gaagaagccc	tagttttact	2640
cagtgattgc	atattcaaca	ccgtcacaga	tcaagaaata	ttcaatagaa	taatagcaga	2700
acagattgca	catgttaa	catttatattc	tgctcctgaa	tttatagcta	caacagaaat	2760
gaatcacgct	atattcaaag	ggcacccata	ttctaacaaa	gtttacggga	cattaaatac	2820
aatcaataat	atcaaccagg	aagacgttgc	attatatata	aaaaatagtt	ttgacaagga	2880
acaaatcggt	atcagcgcag	caggagatgt	agatccaaca	cagctatcaa	atttactaga	2940
taaatatatt	ctttccaaat	tgccatctgg	taataacaaa	aataccatac	cagatacgac	3000
tgттаатaga	gaagacacat	tatttatatgt	acagagagat	gtaccacaaa	gtgtcataat	3060
gtttgctaca	gacacagtac	catatcacag	caaagactat	catgcatcaa	acttgttcaa	3120
tactatgcta	ggcggattaa	gtctcaattc	aatattaatg	atagaattaa	gagacaagtt	3180
aggattaaca	taccatagta	gcagttcact	atctaacatg	aatcatagta	atgtgctatt	3240
tggtacaata	ttcactgata	ataccacagt	aacaaaatgt	atatccgtct	taacagatat	3300
tatagagcac	attaaaaagt	atggagttga	tgaagacact	tttgcaattg	caaaatctag	3360
tattaccaac	tcttttattt	tatctatggt	aaataacaat	aatgttagtg	agatattggt	3420
aagcttacaa	ttacacgatc	tagatccgag	ttatattaat	aaatacaatt	cttactacaa	3480
agcaataaca	atagaagaag	taaataaaat	tgccaagaaa	attttatcta	atgaattagt	3540
aataattgaa	gtaggaaaaa	acaataacat	aatggcaaa	caaatagatg	ctaaaaaaca	3600
catacttgg	taagtataca	ggttattgta	tttactacaa	gtattctatt	aggttgtatt	3660
aagtaagtat	aagtagcttc	aatcaaataa	aaaaacatta	accaaagtgt	tagctctacc	3720
ggagaagctt	attataagct	tttaacctgg	gataatatga	agttttgcta	atgttaagca	3780
aaaaattagt	aatcacaata	tcaaattttc	tttacaggat	tatattgtga	cctaccataa	3840
caacttatat	ttagaaaatg	acaacagata	cacacatcaa	taaattatca	ctacaattca	3900
attaataaaa	caatgagtat	ttttacttaa	ttatttaatt	ttatttttta	aaataaaatt	3960
acaattttac	ttactcaata	aaagcagtta	tactaccaag	tattggatgg	tattaatcgg	4020
agcaattact	acttaatagt	atagctgttg	acaagccgca	atctgcgggt	cttgacaaaa	4080
taatacta	cagttaaa	tttgaagtgt	ttcaccataa	tggtattatt	tatgaaagct	4140
catagcacaa	gtatacggaa	ctttcagcct	ttagaaagag	ctgctataat	cattgcagtg	4200
ttaggtttag	ctgcattctt	gtttgctgct	gctgcctgca	gtgatcgttt	ccaaagattg	4260
caattaacaa	atccatttgt	aatagcagga	atggttggcc	ttgcagttct	tttagttgct	4320

tccttaacag cagcattaag tatatgctta actaaaagta agcaagtcac acaacatgct 4380
 attagacatc gctttggata cgagtcaagc acttcttctt ctgtactgct tgcaatatca 4440
 ataatttctt tattacttgc tgcagcattht tgtggaaaga taatgggtaa tgacaaccca 4500
 gatctattct ttagcaagat gcaagaactc tccaatccac ttgttggtgc agctattgta 4560
 gccgtttctg ttttcctact ctcatctgta atgtatgctg caaagaacat tataagtcca 4620
 gataaacaaa ctacagttat tatattatct aatcaacaaa ctatagaaga agcaaaagta 4680
 gatcaaggaa tgaatatttt gtcagcagta ctcccagcag ctggcattga catcatgact 4740
 atagcttctt gtgacatttt agcagtgagc agccggggat cctctcagca tcaatagatt 4800
 tatgttttag cctgtattca cctttttatt aggtgttgta tcgtttcttt atataagtgt 4860
 gttatattat ataaaacatc taggagttac agttaatttg tttcatgtgg ttattactct 4920
 ttgccattat tattactata cctaaaaata taaaagaatc cgccagggtg aatacaggcc 4980
 aatgtaagtt attgatataa aaatctataa aatcatagac agcaccatat cttattctat 5040
 ctatgatatt tcctattgac cccccaataa tgattacaag aggtaatcta taatgtggct 5100
 gtactataaa taagtagcat aaaacacaag taatcaaat cgagatacta caaaaaacaa 5160
 cattactata ttcaaagtta tttaatatac caaaactaat tccagcattc cacactgtag 5220
 taaagcgcaa gaagcttaat atctctatta cacctttatc tcctatcaaa tttactacat 5280
 accatttact tacctgatc 5299

<210> 2

<211> 522

<212> DNA

<213> Ehrlichia canis

<220>

<221> CDS

<222> (1)..(522)

<223> Protein translated from nucleotides 12 through 533 (cytochrome oxidase homolog).

<400> 2

atg aaa cca aga ata aga aac act att tat gga tta ata gca ata ata 48
 Met Lys Pro Arg Ile Arg Asn Thr Ile Tyr Gly Leu Ile Ala Ile Ile
 1 5 10 15

cta tct atg ata tgt tta gtg tac gct tct gta cca cta tat agt ata 96
 Leu Ser Met Ile Cys Leu Val Tyr Ala Ser Val Pro Leu Tyr Ser Ile
 20 25 30

ttt tgt aaa gta aca ggt tat gga ggt aca gta aga aca agt aat ata 144
 Phe Cys Lys Val Thr Gly Tyr Gly Gly Thr Val Arg Thr Ser Asn Ile
 35 40 45

tca aat tct aaa ata ggt aac act att att aaa gtc aga ttt aat gca 192
 Ser Asn Ser Lys Ile Gly Asn Thr Ile Ile Lys Val Arg Phe Asn Ala
 50 55 60

gat ata cac aaa caa ctg cca tgg aaa ttc tat cca gaa gta tct cat 240
 Asp Ile His Lys Gln Leu Pro Trp Lys Phe Tyr Pro Glu Val Ser His
 65 70 75 80

gta ttt gta aaa cca gga gaa caa aaa ttg att ttc tac cgc gca gaa 288
 Val Phe Val Lys Pro Gly Glu Gln Lys Leu Ile Phe Tyr Arg Ala Glu
 85 90 95

aat cta ctt gat gag gac act tca gga atg gct gta tat aat gtt aca 336
 Asn Leu Leu Asp Glu Asp Thr Ser Gly Met Ala Val Tyr Asn Val Thr
 100 105 110

cca cat aaa gta gga aaa tat ttt aat aag gta gct tgt ttt tgt ttc 384
 Pro His Lys Val Gly Lys Tyr Phe Asn Lys Val Ala Cys Phe Cys Phe
 115 120 125

acc aaa caa aca tta tac cct cat caa aaa act ata atg cca gta tca 432
 Thr Lys Gln Thr Leu Tyr Pro His Gln Lys Thr Ile Met Pro Val Ser
 130 135 140

ttt ttt ata gat cca gcc ata gaa aca gat cct gaa act gct gac gta 480
 Phe Phe Ile Asp Pro Ala Ile Glu Thr Asp Pro Glu Thr Ala Asp Val
 145 150 155 160

aaa ctc atc act ctt tca tat gta ttc ttt aag tac aaa gaa 522
 Lys Leu Ile Thr Leu Ser Tyr Val Phe Phe Lys Tyr Lys Glu
 165 170

<210> 3

<211> 174

<212> PRT

<213> Ehrlichia canis

<400> 3

Met Lys Pro Arg Ile Arg Asn Thr Ile Tyr Gly Leu Ile Ala Ile Ile
 1 5 10 15

Leu Ser Met Ile Cys Leu Val Tyr Ala Ser Val Pro Leu Tyr Ser Ile
 20 25 30

Phe Cys Lys Val Thr Gly Tyr Gly Gly Thr Val Arg Thr Ser Asn Ile
 35 40 45

Ser Asn Ser Lys Ile Gly Asn Thr Ile Ile Lys Val Arg Phe Asn Ala
 50 55 60

Asp Ile His Lys Gln Leu Pro Trp Lys Phe Tyr Pro Glu Val Ser His
 65 70 75 80

Val Phe Val Lys Pro Gly Glu Gln Lys Leu Ile Phe Tyr Arg Ala Glu
 85 90 95

Asn Leu Leu Asp Glu Asp Thr Ser Gly Met Ala Val Tyr Asn Val Thr
 100 105 110

Pro His Lys Val Gly Lys Tyr Phe Asn Lys Val Ala Cys Phe Cys Phe
 115 120 125

Thr Lys Gln Thr Leu Tyr Pro His Gln Lys Thr Ile Met Pro Val Ser
 130 135 140

Phe Phe Ile Asp Pro Ala Ile Glu Thr Asp Pro Glu Thr Ala Asp Val
 145 150 155 160

Lys Leu Ile Thr Leu Ser Tyr Val Phe Phe Lys Tyr Lys Glu
 165 170

<210> 4

<211> 1314

<212> DNA

<213> Ehrlichia canis

<220>

<221> CDS

<222> (1)..(1314)

<223> Protein translated from nucleotides 939 through 2,252 (ProA).

<400> 4

atg atg aaa ttt ttt act tgt ttt ttc ata gtt ttc tta aca ata gcc 48
 Met Met Lys Phe Phe Thr Cys Phe Phe Ile Val Phe Leu Thr Ile Ala
 1 5 10 15

aat cat gct tta tcc ttt aac att aaa gtt aca cat gaa aaa tta gat 96

Asn	His	Ala	Leu	Ser	Phe	Asn	Ile	Lys	Val	Thr	His	Glu	Lys	Leu	Asp		
			20					25					30				
aat	gga	atg	gaa	gta	tac	gtg	att	cca	aat	cat	cgc	gca	cca	gca	gtc	144	
Asn	Gly	Met	Glu	Val	Tyr	Val	Ile	Pro	Asn	His	Arg	Ala	Pro	Ala	Val		
		35					40					45					
atg	cac	atg	gta	tta	tac	aaa	gtc	ggt	gga	act	gat	gat	cca	gta	gga	192	
Met	His	Met	Val	Leu	Tyr	Lys	Val	Gly	Gly	Thr	Asp	Asp	Pro	Val	Gly		
		50				55					60						
tac	tct	gga	tta	gca	cat	ttt	ttt	gaa	cac	tta	atg	ttt	agt	gga	aca	240	
Tyr	Ser	Gly	Leu	Ala	His	Phe	Phe	Glu	His	Leu	Met	Phe	Ser	Gly	Thr		
65					70					75					80		
gaa	aaa	ttt	cct	aat	ctc	atc	agc	aca	ctt	agt	aat	ata	ggc	gga	aat	288	
Glu	Lys	Phe	Pro	Asn	Leu	Ile	Ser	Thr	Leu	Ser	Asn	Ile	Gly	Gly	Asn		
				85					90					95			
ttc	aat	gca	agc	aca	tct	caa	ttt	tgt	act	ata	tac	tac	gaa	tta	ata	336	
Phe	Asn	Ala	Ser	Thr	Ser	Gln	Phe	Cys	Thr	Ile	Tyr	Tyr	Glu	Leu	Ile		
			100					105					110				
cca	aaa	caa	tat	tta	tct	ctt	gca	atg	gat	att	gaa	tca	gac	aga	atg	384	
Pro	Lys	Gln	Tyr	Leu	Ser	Leu	Ala	Met	Asp	Ile	Glu	Ser	Asp	Arg	Met		
		115					120					125					
cag	aat	ttt	aag	gtt	acc	gac	aaa	gca	tta	ata	aga	gaa	caa	aag	gta	432	
Gln	Asn	Phe	Lys	Val	Thr	Asp	Lys	Ala	Leu	Ile	Arg	Glu	Gln	Lys	Val		
	130					135					140						
gtc	tta	gaa	gaa	aga	aaa	atg	aga	gtt	gaa	agc	caa	gca	aaa	aac	ata	480	
Val	Leu	Glu	Glu	Arg	Lys	Met	Arg	Val	Glu	Ser	Gln	Ala	Lys	Asn	Ile		
145					150					155					160		
cta	gaa	gaa	gaa	atg	gaa	aat	gca	ttt	tat	tac	aat	gga	tat	ggc	aga	528	
Leu	Glu	Glu	Glu	Met	Glu	Asn	Ala	Phe	Tyr	Tyr	Asn	Gly	Tyr	Gly	Arg		
				165					170					175			
cca	gta	gta	gga	tgg	gaa	cat	gaa	att	agc	aac	tac	aac	aaa	gaa	gtt	576	
Pro	Val	Val	Gly	Trp	Glu	His	Glu	Ile	Ser	Asn	Tyr	Asn	Lys	Glu	Val		
			180					185					190				
gct	gaa	gcc	ttt	cat	aag	cta	cat	tat	agt	cct	aat	aat	gct	ata	tta	624	
Ala	Glu	Ala	Phe	His	Lys	Leu	His	Tyr	Ser	Pro	Asn	Asn	Ala	Ile	Leu		
		195					200					205					
att	gta	act	gga	gat	gca	gat	cca	caa	gaa	gta	atc	aca	ctt	gca	aaa	672	
Ile	Val	Thr	Gly	Asp	Ala	Asp	Pro	Gln	Glu	Val	Ile	Thr	Leu	Ala	Lys		
	210					215					220						
caa	tac	tat	ggg	aaa	ata	cca	tct	aat	aat	aag	aaa	cct	tca	agt	caa	720	
Gln	Tyr	Tyr	Gly	Lys	Ile	Pro	Ser	Asn	Asn	Lys	Lys	Pro	Ser	Ser	Gln		
225					230					235					240		
gtt	agg	gta	gaa	cca	ccg	cat	aaa	aca	aat	atg	act	tta	aca	tta	aaa	768	
Val	Arg	Val	Glu	Pro	Pro	His	Lys	Thr	Asn	Met	Thr	Leu	Thr	Leu	Lys		
				245					250						255		


```
<210> 5
<211> 438
<212> PRT
<213> Ehrlichia canis
<400> 5
```

Met Met Lys Phe Phe Thr Cys Phe Phe Ile Val Phe Leu Thr Ile Ala
1 5 10 15

Asn His Ala Leu Ser Phe Asn Ile Lys Val Thr His Glu Lys Leu Asp
20 25 30

Asn Gly Met Glu Val Tyr Val Ile Pro Asn His Arg Ala Pro Ala Val
35 40 45

Met His Met Val Leu Tyr Lys Val Gly Gly Thr Asp Asp Pro Val Gly
50 55 60

Tyr Ser Gly Leu Ala His Phe Phe Glu His Leu Met Phe Ser Gly Thr
65 70 75 80

Glu Lys Phe Pro Asn Leu Ile Ser Thr Leu Ser Asn Ile Gly Gly Asn
85 90 95

Phe Asn Ala Ser Thr Ser Gln Phe Cys Thr Ile Tyr Tyr Glu Leu Ile
100 105 110

Pro Lys Gln Tyr Leu Ser Leu Ala Met Asp Ile Glu Ser Asp Arg Met
115 120 125

Gln Asn Phe Lys Val Thr Asp Lys Ala Leu Ile Arg Glu Gln Lys Val
130 135 140

Val Leu Glu Glu Arg Lys Met Arg Val Glu Ser Gln Ala Lys Asn Ile
145 150 155 160

Leu Glu Glu Glu Met Glu Asn Ala Phe Tyr Tyr Asn Gly Tyr Gly Arg
165 170 175

Pro Val Val Gly Trp Glu His Glu Ile Ser Asn Tyr Asn Lys Glu Val
180 185 190

Ala Glu Ala Phe His Lys Leu His Tyr Ser Pro Asn Asn Ala Ile Leu
195 200 205

Ile Val Thr Gly Asp Ala Asp Pro Gln Glu Val Ile Thr Leu Ala Lys
210 215 220

Gln Tyr Tyr Gly Lys Ile Pro Ser Asn Asn Lys Lys Pro Ser Ser Gln
225 230 235 240

10004941000T

Val Arg Val Glu Pro Pro His Lys Thr Asn Met Thr Leu Thr Leu Lys
 245 250 255

Asp Ser Ser Val Glu Ile Pro Glu Leu Phe Leu Met Tyr Gln Ile Pro
 260 265 270

Asn Gly Ile Thr Asn Lys Asn Tyr Ile Leu Asn Met Met Leu Ala Glu
 275 280 285

Ile Leu Gly Ser Gly Lys Phe Ser Leu Leu Tyr Asn Asp Leu Val Ile
 290 295 300

Asn Asn Pro Ile Val Thr Ser Ile Lys Thr Asp Tyr Asn Tyr Leu Thr
 305 310 315 320

Asp Ser Asp Asn Tyr Leu Ser Ile Glu Ala Ile Pro Lys Asn Gly Ile
 325 330 335

Ser Thr Glu Ala Val Glu Gln Glu Ile His Lys Cys Ile Asn Asn Tyr
 340 345 350

Leu Glu Asn Gly Ile Ser Ala Glu Tyr Leu Glu Ser Ala Lys Tyr Lys
 355 360 365

Val Lys Ala His Leu Thr Tyr Ala Phe Asp Gly Leu Thr Phe Ile Ser
 370 375 380

Tyr Phe Tyr Gly Met His Leu Ile Leu Gly Val Pro Leu Ser Glu Ile
 385 390 395 400

Ser Asn Ile Tyr Asp Thr Ile Asp Lys Val Ser Ile Gln Asp Val Asn
 405 410 415

Ser Ala Met Glu Asn Ile Phe Gln Asn Asn Ile Arg Leu Thr Gly His
 420 425 430

Leu Leu Pro Asn Gly Glu
 435

<210> 6

<211> 1353

<212> DNA

10004494-10001

<213> Ehrlichia canis

<220>

<221> CDS

<222> (1)..(1353)

<223> Protein translated from nucleotides 2,258 through 3,610 (ProB).

<400> 6

atg aga aac ata ttg tgt tac aca tta ata ttg att ttc ttt tca ttc	48
Met Arg Asn Ile Leu Cys Tyr Thr Leu Ile Leu Ile Phe Phe Ser Phe	
1 5 10 15	
aat aca tat gca aat gat ctc aat att aac ata aaa gaa gct aca act	96
Asn Thr Tyr Ala Asn Asp Leu Asn Ile Asn Ile Lys Glu Ala Thr Thr	
20 25 30	
aaa aat aaa ata cac tat cta tat gtt gaa cat cat aac cta cca aca	144
Lys Asn Lys Ile His Tyr Leu Tyr Val Glu His His Asn Leu Pro Thr	
35 40 45	
att tcc tta aaa ttt gca ttc aag aaa gca gga tac gct tat gat gcc	192
Ile Ser Leu Lys Phe Ala Phe Lys Lys Ala Gly Tyr Ala Tyr Asp Ala	
50 55 60	
ttt gat aag caa gga ctt gca tac ttt aca tca aaa ata tta aac gaa	240
Phe Asp Lys Gln Gly Leu Ala Tyr Phe Thr Ser Lys Ile Leu Asn Glu	
65 70 75 80	
gga tca aaa aac aac tat gct ctc agt ttt gca caa caa tta gaa ggc	288
Gly Ser Lys Asn Asn Tyr Ala Leu Ser Phe Ala Gln Gln Leu Glu Gly	
85 90 95	
aaa ggt ata gac tta aaa ttt gat ata gac cta gac aat ttt tat ata	336
Lys Gly Ile Asp Leu Lys Phe Asp Ile Asp Leu Asp Asn Phe Tyr Ile	
100 105 110	
tca tta aaa acc tta tca gaa aac ttt gaa gaa gcc cta gtt tta ctc	384
Ser Leu Lys Thr Leu Ser Glu Asn Phe Glu Glu Ala Leu Val Leu Leu	
115 120 125	
agt gat tgc ata ttc aac acc gtc aca gat caa gaa ata ttc aat aga	432
Ser Asp Cys Ile Phe Asn Thr Val Thr Asp Gln Glu Ile Phe Asn Arg	
130 135 140	
ata ata gca gaa cag att gca cat gtt aaa tca tta tat tct gct cct	480
Ile Ile Ala Glu Gln Ile Ala His Val Lys Ser Leu Tyr Ser Ala Pro	
145 150 155 160	
gaa ttt ata gct aca aca gaa atg aat cac gct ata ttc aaa ggg cac	528
Glu Phe Ile Ala Thr Thr Glu Met Asn His Ala Ile Phe Lys Gly His	
165 170 175	
cca tat tct aac aaa gtt tac ggg aca tta aat aca atc aat aat atc	576
Pro Tyr Ser Asn Lys Val Tyr Gly Thr Leu Asn Thr Ile Asn Asn Ile	
180 185 190	

10004494-10001

aac cag gaa gac gtt gca tta tat ata aaa aat agt ttt gac aag gaa Asn Gln Glu Asp Val Ala Leu Tyr Ile Lys Asn Ser Phe Asp Lys Glu 195 200 205	624
caa atc gtt atc agc gca gca gga gat gta gat cca aca cag cta tca Gln Ile Val Ile Ser Ala Ala Gly Asp Val Asp Pro Thr Gln Leu Ser 210 215 220	672
aat tta cta gat aaa tat att ctt tcc aaa ttg cca tct ggt aat aac Asn Leu Leu Asp Lys Tyr Ile Leu Ser Lys Leu Pro Ser Gly Asn Asn 225 230 235 240	720
aaa aat acc ata cca gat acg act gtt aat aga gaa gac aca tta tta Lys Asn Thr Ile Pro Asp Thr Thr Val Asn Arg Glu Asp Thr Leu Leu 245 250 255	768
tat gta cag aga gat gta cca caa agt gtc ata atg ttt gct aca gac Tyr Val Gln Arg Asp Val Pro Gln Ser Val Ile Met Phe Ala Thr Asp 260 265 270	816
aca gta cca tat cac agc aaa gac tat cat gca tca aac ttg ttc aat Thr Val Pro Tyr His Ser Lys Asp Tyr His Ala Ser Asn Leu Phe Asn 275 280 285	864
act atg cta ggc gga tta agt ctc aat tca ata tta atg ata gaa tta Thr Met Leu Gly Gly Leu Ser Leu Asn Ser Ile Leu Met Ile Glu Leu 290 295 300	912
aga gac aag tta gga tta aca tac cat agt agc agt tca cta tct aac Arg Asp Lys Leu Gly Leu Thr Tyr His Ser Ser Ser Ser Leu Ser Asn 305 310 315 320	960
atg aat cat agt aat gtg cta ttt ggt aca ata ttc act gat aat acc Met Asn His Ser Asn Val Leu Phe Gly Thr Ile Phe Thr Asp Asn Thr 325 330 335	1008
aca gta aca aaa tgt ata tcc gtc tta aca gat att ata gag cac att Thr Val Thr Lys Cys Ile Ser Val Leu Thr Asp Ile Ile Glu His Ile 340 345 350	1056
aaa aag tat gga gtt gat gaa gac act ttt gca att gca aaa tct agt Lys Lys Tyr Gly Val Asp Glu Asp Thr Phe Ala Ile Ala Lys Ser Ser 355 360 365	1104
att acc aac tct ttt att tta tct atg tta aat aac aat aat gtt agt Ile Thr Asn Ser Phe Ile Leu Ser Met Leu Asn Asn Asn Asn Val Ser 370 375 380	1152
gag ata ttg tta agc tta caa tta cac gat cta gat ccg agt tat att Glu Ile Leu Leu Ser Leu Gln Leu His Asp Leu Asp Pro Ser Tyr Ile 385 390 395 400	1200
aat aaa tac aat tct tac tac aaa gca ata aca ata gaa gaa gta aat Asn Lys Tyr Asn Ser Tyr Tyr Lys Ala Ile Thr Ile Glu Glu Val Asn 405 410 415	1248
aaa att gcc aag aaa att tta tct aat gaa tta gta ata att gaa gta Lys Ile Ala Lys Lys Ile Leu Ser Asn Glu Leu Val Ile Ile Glu Val	1296

10004494-10201

420 425 430
 gga aaa aac aat aac ata aat ggc aaa caa ata gat gct aaa aaa cac 1344
 Gly Lys Asn Asn Asn Ile Asn Gly Lys Gln Ile Asp Ala Lys Lys His
 435 440 445
 ata ctt ggt 1353
 Ile Leu Gly
 450
 <210> 7
 <211> 451
 <212> PRT
 <213> Ehrlichia canis
 <400> 7
 Met Arg Asn Ile Leu Cys Tyr Thr Leu Ile Leu Ile Phe Phe Ser Phe
 1 5 10 15
 Asn Thr Tyr Ala Asn Asp Leu Asn Ile Asn Ile Lys Glu Ala Thr Thr
 20 25 30
 Lys Asn Lys Ile His Tyr Leu Tyr Val Glu His His Asn Leu Pro Thr
 35 40 45
 Ile Ser Leu Lys Phe Ala Phe Lys Lys Ala Gly Tyr Ala Tyr Asp Ala
 50 55 60
 Phe Asp Lys Gln Gly Leu Ala Tyr Phe Thr Ser Lys Ile Leu Asn Glu
 65 70 75 80
 Gly Ser Lys Asn Asn Tyr Ala Leu Ser Phe Ala Gln Gln Leu Glu Gly
 85 90 95
 Lys Gly Ile Asp Leu Lys Phe Asp Ile Asp Leu Asp Asn Phe Tyr Ile
 100 105 110
 Ser Leu Lys Thr Leu Ser Glu Asn Phe Glu Glu Ala Leu Val Leu Leu
 115 120 125
 Ser Asp Cys Ile Phe Asn Thr Val Thr Asp Gln Glu Ile Phe Asn Arg
 130 135 140
 Ile Ile Ala Glu Gln Ile Ala His Val Lys Ser Leu Tyr Ser Ala Pro
 145 150 155 160

FOOTNOTES: 10004494-10007

Glu Phe Ile Ala Thr Thr Glu Met Asn His Ala Ile Phe Lys Gly His
165 170 175

Pro Tyr Ser Asn Lys Val Tyr Gly Thr Leu Asn Thr Ile Asn Asn Ile
180 185 190

Asn Gln Glu Asp Val Ala Leu Tyr Ile Lys Asn Ser Phe Asp Lys Glu
195 200 205

Gln Ile Val Ile Ser Ala Ala Gly Asp Val Asp Pro Thr Gln Leu Ser
210 215 220

Asn Leu Leu Asp Lys Tyr Ile Leu Ser Lys Leu Pro Ser Gly Asn Asn
225 230 235 240

Lys Asn Thr Ile Pro Asp Thr Thr Val Asn Arg Glu Asp Thr Leu Leu
245 250 255

Tyr Val Gln Arg Asp Val Pro Gln Ser Val Ile Met Phe Ala Thr Asp
260 265 270

Thr Val Pro Tyr His Ser Lys Asp Tyr His Ala Ser Asn Leu Phe Asn
275 280 285

Thr Met Leu Gly Gly Leu Ser Leu Asn Ser Ile Leu Met Ile Glu Leu
290 295 300

Arg Asp Lys Leu Gly Leu Thr Tyr His Ser Ser Ser Ser Leu Ser Asn
305 310 315 320

Met Asn His Ser Asn Val Leu Phe Gly Thr Ile Phe Thr Asp Asn Thr
325 330 335

Thr Val Thr Lys Cys Ile Ser Val Leu Thr Asp Ile Ile Glu His Ile
340 345 350

Lys Lys Tyr Gly Val Asp Glu Asp Thr Phe Ala Ile Ala Lys Ser Ser
355 360 365

Ile Thr Asn Ser Phe Ile Leu Ser Met Leu Asn Asn Asn Asn Val Ser
370 375 380

Glu Ile Leu Leu Ser Leu Gln Leu His Asp Leu Asp Pro Ser Tyr Ile

10004494-110001

```

<210>      8
<211>      663
<212>      DNA
<213>      Ehrlichia canis
<220>
<221>      CDS
<222>      (1)..(663)
<223>      Protein translated from nucleotides 4,132 through 4,794 (mmpA) .
<400>      8
atg aaa gct cat agc aca agt ata cgg aac ttt cag cct tta gaa aga          48
Met Lys Ala His Ser Thr Ser Ile Arg Asn Phe Gln Pro Leu Glu Arg
1              5              10              15

gct gct ata atc att gca gtg tta ggt tta gct gca ttc ttg ttt gct          96
Ala Ala Ile Ile Ile Ala Val Leu Gly Leu Ala Ala Phe Leu Phe Ala
              20              25              30

gct gct gcc tgc agt gat cgt ttc caa aga ttg caa tta aca aat cca          144
Ala Ala Ala Cys Ser Asp Arg Phe Gln Arg Leu Gln Leu Thr Asn Pro
              35              40              45

ttt gta ata gca gga atg gtt ggc ctt gca gtt ctt tta gtt gct tcc          192
Phe Val Ile Ala Gly Met Val Gly Leu Ala Val Leu Leu Val Ala Ser
              50              55              60

tta aca gca gca tta agt ata tgc tta act aaa agt aag caa gtc aca          240
Leu Thr Ala Ala Leu Ser Ile Cys Leu Thr Lys Ser Lys Gln Val Thr
65              70              75              80

caa cat gct att aga cat cgc ttt gga tac gag tca agc act tct tct          288
Gln His Ala Ile Arg His Arg Phe Gly Tyr Glu Ser Ser Thr Ser Ser
              85              90              95

```


tct gta ctg ctt gca ata tca ata att tct tta tta ctt gct gca gca 336
 Ser Val Leu Leu Ala Ile Ser Ile Ile Ser Leu Leu Leu Ala Ala Ala
 100 105 110

ttt tgt gga aag ata atg ggt aat gac aac cca gat cta ttc ttt agc 384
 Phe Cys Gly Lys Ile Met Gly Asn Asp Asn Pro Asp Leu Phe Phe Ser
 115 120 125

aag atg caa gaa ctc tcc aat cca ctt gtt gtt gca gct att gta gcc 432
 Lys Met Gln Glu Leu Ser Asn Pro Leu Val Val Ala Ala Ile Val Ala
 130 135 140

gtt tct gtt ttc cta ctc tca ttc gta atg tat gct gca aag aac att 480
 Val Ser Val Phe Leu Leu Ser Phe Val Met Tyr Ala Ala Lys Asn Ile
 145 150 155 160

ata agt cca gat aaa caa act cac gtt att ata tta tct aat caa caa 528
 Ile Ser Pro Asp Lys Gln Thr His Val Ile Ile Leu Ser Asn Gln Gln
 165 170 175

act ata gaa gaa gca aaa gta gat caa gga atg aat att ttg tca gca 576
 Thr Ile Glu Glu Ala Lys Val Asp Gln Gly Met Asn Ile Leu Ser Ala
 180 185 190

gta ctc cca gca gct ggc att gac atc atg act ata gct tct tgt gac 624
 Val Leu Pro Ala Ala Gly Ile Asp Ile Met Thr Ile Ala Ser Cys Asp
 195 200 205

att tta gca gtg agc agc cgg gga tcc tct cag cat caa 663
 Ile Leu Ala Val Ser Ser Arg Gly Ser Ser Gln His Gln
 210 215 220

<210> 9

<211> 221

<212> PRT

<213> Ehrlichia canis

<400> 9

Met Lys Ala His Ser Thr Ser Ile Arg Asn Phe Gln Pro Leu Glu Arg
 1 5 10 15

Ala Ala Ile Ile Ile Ala Val Leu Gly Leu Ala Ala Phe Leu Phe Ala
 20 25 30

Ala Ala Ala Cys Ser Asp Arg Phe Gln Arg Leu Gln Leu Thr Asn Pro
 35 40 45

Phe Val Ile Ala Gly Met Val Gly Leu Ala Val Leu Leu Val Ala Ser
 50 55 60

<223> Protein translated from complementary sequence derived from nucleotides 4,883 through 5,299 (partial lipoprotein signal peptidase homolog).

<400> 10

gat cag gta agt aaa tgg tat gta gta aat ttg ata gga gat aaa ggt 48
 Asp Gln Val Ser Lys Trp Tyr Val Val Asn Leu Ile Gly Asp Lys Gly
 1 5 10 15

gta ata gag ata tta agc ttc ttg cgc ttt act aca gtg tgg aat cct 96
 Val Ile Glu Ile Leu Ser Phe Leu Arg Phe Thr Thr Val Trp Asn Pro
 20 25 30

gga att agt ttt ggt ata tta aat aac ttt gaa tat agt aat gtt gtt 144
 Gly Ile Ser Phe Gly Ile Leu Asn Asn Phe Glu Tyr Ser Asn Val Val
 35 40 45

ttt tgt agt atc tcg att ttg att act tgt gtt tta tgc tac tta ttt 192
 Phe Cys Ser Ile Ser Ile Leu Ile Thr Cys Val Leu Cys Tyr Leu Phe
 50 55 60

ata gta cag cca cat tat aga tta cct ctt gta atc att att ggg ggg 240
 Ile Val Gln Pro His Tyr Arg Leu Pro Leu Val Ile Ile Ile Gly Gly
 65 70 75 80

tca ata gga aat atc ata gat aga ata aga tat ggt gct gtc tat gat 288
 Ser Ile Gly Asn Ile Ile Asp Arg Ile Arg Tyr Gly Ala Val Tyr Asp
 85 90 95

ttt ata gat ttt tat atc aat aac tta cat tgg cct gta ttc aac ctg 336
 Phe Ile Asp Phe Tyr Ile Asn Asn Leu His Trp Pro Val Phe Asn Leu
 100 105 110

gcg gat tct ttt ata ttt tta ggt ata gta ata ata atg gca aag agt 384
 Ala Asp Ser Phe Ile Phe Leu Gly Ile Val Ile Ile Met Ala Lys Ser
 115 120 125

aat aac cac atg aaa caa att aac tgt aac tcc 417
 Asn Asn His Met Lys Gln Ile Asn Cys Asn Ser
 130 135

<210> 11

<211> 139

<212> PRT

<213> Ehrlichia canis

<400> 11

Asp Gln Val Ser Lys Trp Tyr Val Val Asn Leu Ile Gly Asp Lys Gly
 1 5 10 15

Val Ile Glu Ile Leu Ser Phe Leu Arg Phe Thr Thr Val Trp Asn Pro
 20 25 30

Gly Ile Ser Phe Gly Ile Leu Asn Asn Phe Glu Tyr Ser Asn Val Val
 35 40 45

Phe Cys Ser Ile Ser Ile Leu Ile Thr Cys Val Leu Cys Tyr Leu Phe
50 55 60

Ile Val Gln Pro His Tyr Arg Leu Pro Leu Val Ile Ile Ile Gly Gly
65 70 75 80

Ser Ile Gly Asn Ile Ile Asp Arg Ile Arg Tyr Gly Ala Val Tyr Asp
85 90 95

Phe Ile Asp Phe Tyr Ile Asn Asn Leu His Trp Pro Val Phe Asn Leu
100 105 110

Ala Asp Ser Phe Ile Phe Leu Gly Ile Val Ile Ile Met Ala Lys Ser
115 120 125

Asn Asn His Met Lys Gln Ile Asn Cys Asn Ser
130 135

<210> 12

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artifical Sequence: oligonucleotide

<400> 12

aggcttggtc agggatgaaga agaatccaac gacaaaagct t

41

<210> 13

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: oligonucleotide

<400> 13

aagcttttgt cggttgattc ttcttcaccc tgaacttgcc a

41

TOOFT-1644001

FOOT" 45400T